Drug-eluting stents - what should be improved?

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Drug-eluting stents (DES) have reduced restenosis but present challenges like stent thrombosis and polymer-related issues.
• Incomplete restenosis inhibition, particularly in complex lesions, necessitates further innovation.
• Existing DES face limitations including polymer durability and potential late adverse events.

Purpose of the Study:

• To review novel drug-eluting stent systems designed to overcome limitations of current DES.
• To explore advancements in stent coatings, polymer technology, and bioabsorbable stent designs.
• To assess the potential of new stent technologies to improve safety and efficacy in coronary interventions.

Main Methods:

• Review of second-generation DES incorporating rapamycin analogues (zotarolimus, everolimus, biolimus).
• Analysis of stent coatings designed for enhanced endothelial healing and reduced restenosis.
• Investigation of biocompatible, bioabsorbable polymers, and polymer-free DES delivery systems.
• Examination of bioabsorbable polymeric and metallic stents for reduced late complications.

Main Results:

• Second-generation DES utilize advanced drugs and coatings to mitigate restenosis and thrombosis.
• Development of bioabsorbable polymers and polymer-free systems aims to reduce long-term adverse effects.
• Bioabsorbable stents show promise in minimizing late complications associated with permanent implants.

Conclusions:

• Innovative DES technologies, including advanced coatings and bioabsorbable materials, are emerging to address current limitations.
• While initial results are promising, extensive long-term clinical trials are crucial to validate the superiority of novel DES.
• Further research is essential to establish the long-term safety and efficacy of these next-generation stent systems compared to first-generation DES.